Health Care • Biotechnology: Pharmaceutical Preparations
LFCR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-05-25 | FY 2023
FILED 2023-05-26 |
|---|---|---|---|
| Revenue (Total Sales) | $97.5M | $128.9M | $24.8M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | $40.3M | — |
| Gross Margin % | — | 31.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | -$17.2M | -$8.8M |
| Operating Margin % | — | -13.4% | — |
| Net Income (GAAP) | $0 | -$38.7M | $12.0M |
| EBITDA (Normalized) | — | -$6.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | — | -$206.0K | $257.0K |
| Capital Expenditures (CapEx) | — | $13.4M | — |
| Free Cash Flow (FCF) | — | -$13.6M | $257.0K |
| FCF Margin % | — | -10.6% | — |
| Return on Invested Capital (ROIC %) | — | -11.7% | — |
| Cash & Short-Term Equivalents | $17.5M | $9.5M | — |
| Total Debt (Short + Long Term) | — | $110.5M | — |
| Total Stockholders' Equity | -$14.2M | $15.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LFCR.